Information Provided By:
Fly News Breaks for February 14, 2019
INCY
Feb 14, 2019 | 12:51 EDT
Piper Jaffray analyst Tyler Van Buren reiterated an Overweight rating and $85 price target on Incyte following the company's "good" Q4 results. In a research note to investors, the analyst says Jakafi continues to be a "workhorse," and feels guidance for 2019 "appears achievable" as Jakafi continues to grow. Van Buren says he also found management's comments regarding potential future strategic transactions for late-stage commercial assets in the hematology oncology space "interesting," which could serve to further inflect revenues, and believes that pipeline readouts in the various GvHD and dermatology indications will be key to additional upside from these levels.
News For INCY From the Last 2 Days
There are no results for your query INCY